|Bid||92.60 x 900|
|Ask||259.99 x 1100|
|Day's range||226.28 - 236.11|
|52-week range||217.20 - 460.21|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||28.35|
|Earnings date||02 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||332.18|
Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.